PTPN22

PTPN22 rs12730735 — The Haplotype Refiner Behind the Autoimmune Switch

PTPN22 encodes lymphoid tyrosine phosphatase (LYP), the master negative regulator of T-cell and B-cell activation. While the R620W missense variant (rs2476601) is
the most studied variant in this gene, the PTPN22 locus harbors additional variation that modifies autoimmune risk in ways R620W alone cannot capture.
rs12730735 is an intronic variant that serves as a haplotype tag SNP | Tag SNPs mark a specific chromosomal segment containing several variants in high linkage
disequilibrium, allowing them to be used as proxies for the entire block's effects, tracking a distinct
chromosomal segment of the PTPN22 locus across diverse populations.

The Mechanism

rs12730735 lies within an intron of PTPN22, producing no amino acid change. Its biological effect operates through linkage disequilibrium: the C allele marks a
specific chromosomal background within the PTPN22 locus that may carry regulatory variants affecting gene expression, splicing, or transcription factor
binding in immune cells. PTPN22 expression is tightly regulated in lymphocytes | Expression studies show PTPN22 is predominantly expressed in lymphoid
tissue; intronic variants can affect mRNA processing and expression levels, and intronic variants in regulatory
regions can alter these expression dynamics without changing the protein sequence. In East Asian populations, where R620W is essentially absent (allele
frequency ~1%), rs12730735 provides an independent window into PTPN22-linked autoimmune susceptibility — a population that the R620W-centric research
framework largely misses.

The Evidence

The most direct evidence for rs12730735 comes from a three-SNP PTPN22 analysis in rheumatoid arthritis | Bourgey et al. examined rs2476601, rs12730735,
and rs11102685 together to model PTPN22 effect on RA; combining all three expanded the risk range from GRR 1–2.7 to 1–4.7 compared to using R620W
alone. When rs12730735 and rs11102685 were added to the R620W-based risk model, the genotypic risk ratio
range expanded substantially — from a maximum of approximately 2.7-fold to 4.7-fold — uncovering high-risk subgroups among individuals who appeared
identical on R620W status alone. Individuals in the highest genotypic class faced roughly four times the RA risk of the reference group (GRR > 3, confirmed
by identity-by-descent excess in sib pairs).

In a Korean population study where R620W is non-polymorphic, rs12730735 minor allele (C) and a five-SNP haplotype (GGCTT) showed significant association
with autoimmune thyroid disease | Lee et al. found p < 0.01 for the rs12730735 minor allele in AITD, specifically Hashimoto's thyroiditis; the R620W variant
was absent from this population. This study included 389 T1D patients, 212 AITD patients, and 225 controls.
Notably, no association was found with type 1 diabetes in this cohort, suggesting rs12730735's primary signal relates to thyroid autoimmunity in populations
where R620W does not confound the analysis. This independence makes it especially informative for the ~60% of the world's population with Asian ancestry.

For RA in European populations, a well-powered study of 4,460 RA cases and 4,481 controls | Wan Taib et al. found no independent PTPN22 effect on RA
beyond R620W in 4,460 European cases; rs12730735's RA association in this population is explained by its LD with R620W
found no evidence of RA risk beyond R620W. This suggests rs12730735's RA association in Europeans is largely mediated through co-inheritance with R620W
haplotypes rather than an independent causal effect — but the Korean data indicates the variant's chromosomal segment has autoimmune relevance beyond R620W.

More recently, a Polish study of T1D patients | Cichocka et al. found CT genotype of rs12730735 associated with improved glycemic control in 277 T1D
patients found that the CT genotype of rs12730735 was associated with improved likelihood of achieving
glycemic control — an intriguing finding that may reflect modulation of immune-mediated beta-cell destruction rates in T1D.

Practical Actions

For carriers of the C allele, the actionable picture is nuanced by ancestry. In European populations, rs12730735 generally co-occurs with R620W haplotypes
when present on risk-associated backgrounds, meaning the main autoimmune monitoring guidance is similar to R620W carriers. In Asian populations, rs12730735
provides an independent signal for Hashimoto's thyroiditis risk — the most common autoimmune thyroid condition. Carriers should be attentive to thyroid
symptoms and consider periodic thyroid function monitoring. Individuals with East Asian ancestry who carry the C allele and have a family history of thyroid
autoimmunity are the clearest beneficiaries of proactive thyroid screening.

Interactions

The most important interaction is with rs2476601 (R620W). In Europeans, these two variants tend to co-segregate on the same haplotype; the three-SNP
combination rs2476601 + rs12730735 + rs11102685 creates more granular risk stratification than R620W alone. When an individual carries the R620W risk
allele alongside rs12730735-C, the combined genotypic risk ratio may reach 4-fold or higher — a substantially elevated risk not captured by R620W alone.
This interaction is documented in the Bourgey 2007 analysis.

A proposed compound action should be considered for individuals who carry both rs2476601 risk allele (A/G or A/A) and rs12730735 C allele — especially
for early and intensive autoimmune monitoring given the synergistic risk elevation.